EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Feasibility demonstration of a device for vitreous liquid biopsy incidental to intravitreal injection

Alexandre R Tumlinson iD, Jennifer M Calara, Dimitri T Azar, Anthony P Adamis, Demetrios G Vavvas, Jay M Stewart

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0294526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Alexandre R Tumlinson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Twenty / Twenty Therapeutics LLC, South San Francisco, California, United States of America. Hauptthemen laut MEDLINE: Proteomics, Insulins. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Twenty / Twenty Therapeutics, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

VitreoDx is an experimental device enabling push-button collection of a neat vitreous liquid biopsy incidental to an intravitreal injection. We explored the ability of the device to collect a sample usable for proteomic biomarker discovery and testing.

Design

Pilot study using ex vivo human eyes.

Methods

Non-vitrectomized, human eyes from nine donors 75–91 years of age were refrigerated in BSS and used within 5 days of death. Four VitreoDx devices fitted with 25G needles, and four staked needle insulin syringes with 30G needles, were inserted at equal intervals through the pars plana of each eye and held in place by a fixture. The sampling mode of each VitreoDx device was triggered to attempt to acquire a liquid biopsy up to 70 μL. The plunger of each insulin syringe was retracted to attempt to obtain a liquid biopsy with a maximum volume of 50 μL. Samples acquired with the VitreoDx were extracted to polypropylene cryovials, refrigerated to -80 ºC, and sent for offsite proteomic analysis by proximity extension assay with a focus on panels containing approved and pipelined drug targets for neovascular disease and inflammatory factors.

Results

Of the attempted liquid biopsies with the novel 25G VitreoDx, 92% (66 of 72) resulted in successful acquisition (>25 μL) while 89% (64 of 72) attempted by a traditional 30G needle resulted in a successful acquisition. Sample volume sufficient for proteomics array analysis was acquired by the VitreoDx for every eye. Detectable protein was found for 151 of 166 unique proteins assayed in at least 25% of eyes sampled by VitreoDx.

Conclusions

The high acquisition rate achieved by the prototype was similar to that achieved in previous clinical studies where a standard syringe was used with a 25G needle to biopsy vitreous fluid directly prior to standard intravitreal injection. Successful aspiration rates were likewise high for 30G needles. Together, these suggest that it is possible to routinely acquire liquid vitreous biopsies from patients who typically receive intravitreal injections with an injection device using a standard size needle without a vitreous cutter. Protein analysis shows that proteins of interest survive the sampling mechanism and may have potential to direct care in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsInsulinsHumansInfant, NewbornIntravitreal InjectionsFeasibility StudiesPilot ProjectsVitreous BodyBiopsyNeedlesLiquid Biopsy

Substanzen

Insulins

Autor:innen und Institutionen

  • Twenty / Twenty Therapeutics LLC, South San Francisco, California, United States of America.
  • Department of Ophthalmology, Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States of America.
  • Department of Ophthalmology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States of America.

ORCID-Profile: Alexandre R Tumlinson

Förderung

  • Twenty / Twenty Therapeutics, LLC

Zitieren

APA

Tumlinson, A. R., Calara, J. M., Azar, D. T., Adamis, A. P., Vavvas, D. G., & Stewart, J. M. (2024). Feasibility demonstration of a device for vitreous liquid biopsy incidental to intravitreal injection. PLOS ONE. https://doi.org/10.1371/journal.pone.0294526

Vancouver

Tumlinson AR, Calara JM, Azar DT, Adamis AP, Vavvas DG, Stewart JM. Feasibility demonstration of a device for vitreous liquid biopsy incidental to intravitreal injection. PLOS ONE. 2024. doi:10.1371/journal.pone.0294526

BibTeX
@article{Tumlinson2024,
  author = {Tumlinson, Alexandre R and Calara, Jennifer M and Azar, Dimitri T and Adamis, Anthony P and Vavvas, Demetrios G and Stewart, Jay M},
  title = {Feasibility demonstration of a device for vitreous liquid biopsy incidental to intravitreal injection},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0294526}
}
Kostenlos starten →